Dr. Falk is a Professor of Neurology and of Pharmacology, and he is the Director of the Preclinical Parkinson's disease Laboratory.  He has received his PhD from the University of Hamburg, Germany.  Dr. Falk is the author of over 45 peer-reviewed journal publications, with an h-index of 21, an I-10-index of 30, and over 140 peer-reviewed abstracts and conference presentations. He holds two patents and his work has led to ongoing Clinical trials testing a novel treatment for levodopa-induced dyskinesias. He is also Co-founder and equity partner in Teleport Pharmaceuticals, LLC. He is a Member of the Grant Review Committee for the Parkinson's Foundation (PF) and is Standing member of the NIH Clinical Neurotransmitters and Neuroplasticity (CNNT) study section, as well as an ad hoc reviewer for the Michael J. Fox Foundation for Parkinson's Research and the Parkinson’s UK Foundation.